T. Rowe Price Equity Income ETF · AMEX:TEQI
T. Rowe Price Equity Income ETF — T. Rowe Price — Investor Presentation (May 2025)
26 slides from T. Rowe Price Equity Income ETF's investor presentation, May 13, 2025
Slide 1: Digging Deeper into US Structured Research
Digging Deeper into US Structured Research Alexa Gagliardi, CFA Portfolio Manager 13 May 2025 FOR INVESTMENT PROFESSIONALS ONLY. NOT FOR FURTHER DISTRIBUTION.
Slide 2: Digging Deeper into US Structured Research
Digging Deeper into US Structured Research Alexa Gagliardi Portfolio Manager T. R O W E P R I C E 2
Slide 3: Risks
Risks The following risks are materially relevant to the Structured Research Equity portfolios: ▪ Equity - Equities can lose value rapidly for a variety of reasons and can remain at low prices indefinitely. ▪ Geographic concentration - Geographic concentration risk may result in performance being mo
Slide 4: Long History of Strong Risk-Adjusted Returns
Long History of Strong Risk-Adjusted Returns Since its inception over 25 years ago, strong bottom- up security selection combined with sound risk oversight and portfolio construction principles, has allowed our US Structured Research Strategy to deliver clients with consistently strong risk-adjusted
Slide 5: What is US Structured Research Equity?
What is US Structured Research Equity? US Structured Seeks to add value via Portfolio weighting Limited key man risk with stock selection with decisions are made by ~30 participating analysts Research Equity benchmark-like volatility sector/industry experts and oversight team and characteristics is
Slide 6: How is it implemented?
How is it implemented? Analyst sub-portfolios Allocate capital to analysts Analysts have autonomy Portfolio construction rules in proportion to their to determine relative facilitate risk management with risk management respective coverage in the security weights and process, controlling active rele
Slide 7: T. Rowe Price Associates Equity Research Team
T. Rowe Price Associates Equity Research Team As of 31 March 2025 BAL Baltimore DC Washington DC HKG Hong Kong LON London MEL Melbourne NYC New York SFO San Francisco SHA Shanghai SGP Singapore SYD Sydney TOK Tokyo HEAD OF EQUITY: Joshua Nelson, Head of Global Equity (BAL) HEAD OF GLOBAL EQUITY RESE
Slide 8: The Sleeve of a US Industrials Analyst
The Sleeve of a US Industrials Analyst Market cap determines sleeve size Own most compelling names As of 31 March 2025 % of US SRS Analyst Sector Portfolio Analyst Allocation Tony Wang Information Technology 16.77% Chris Graff Communication Services 11.14 Ken W. Allen Information Technology 7.54 Ari
Slide 9: Portfolio Oversight Team
US Structured Research Portfolio Oversight Team As of 31 March 2025 US Directors of Equity Research Dedicated Strategy PM Portfolio Specialists Ann Holcomb, CFA Jason Nogueira, CFA Jason Polun, CFA Alexa Gagliardi, CFA Tamzin Manning Eric Papesh, CFA Director of Equity Director of Equity Director of
Slide 10: Market-like Exposures to Key Risk Factors
Market-like Exposures to Key Risk Factors As of 31 March 2025 US STRUCTURED RESEARCH EQUITY REPRESENTATIVE PORTFOLIO WEIGHT VS. S&P 500 INDEX2 WEIGHT Sectors Industries Styles1 Financials U.S. Dividend Yield Software U.S. Long-term Reversal Information Technology Financial Services U.S. Management Q
Slide 11: Performance – US Structured Research Equity Composite
Performance – US Structured Research Equity Composite Periods Ended 31 March 2025 Figures are Calculated in U.S. Dollars Annualised Three One Three Five Ten Fifteen Months Year Years Years Years Years US Structured Research Equity Composite -4.76% 8.25% 10.48% 19.94% 13.64% 13.94% (Gross of Fees) US
Slide 12: Security Selection Consistent Source of Added Value
Security Security Selection Consistent Source of Added Value selection drives alpha 10 Years Ended 31 March 2025 US STRUCTURED RESEARCH EQUITY REPRESENTATIVE PORTFOLIO WEIGHT VS. S&P 500 INDEX1 Sector Attribution Analysis (USD) Total 2.0 Information Technology Total Value Added Financials 1.5 Sector
Slide 13: Better Investment Outcomes – More Returns, More Often
Better Investment Outcomes – More Returns, More Often As of 31 March 2025 One-Year Excess Returns (annualized) 78% Hit rate* % 10.00 8.00 +1.04% 6.00 Average excess return 4.00 2.00 0.00 -2.00 -4.00 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2
Slide 14: Strong Performance Across Wide Range of Markets
Strong Performance Across Wide Range of Markets As of 31 March 2025 Growth-Market Excess Returns1 Value-Market Excess Returns1 % 10.0 81% % 10.0 74% Hit rate* Hit rate* 8.0 8.0 +1.2% 6.0 +0.8% 6.0 Average excess return 4.0 Average excess return 4.0 2.0 2.0 0.0 0.0 -2.0 -2.0 -4.0 2000 2001 2002 2003
Slide 15: SRS Advantage vs. Passive—The Power of Compounding Alpha
SRS Advantage vs. Passive—The Power of Compounding Alpha 31 May 1999 (Since Inception) Through 31 March 2025 Annualised 6.0 US Structured Research Equity Composite (Net of Fees) Return (%) Hypothetical Account Value 5.0 eVestment US Large Cap Core Equity Peer Group Average 8.93 (USD, in billions) 4.
Slide 16: A “Structured” Approach to Address Clients’ ESG Considerations
A “Structured” Approach to Address Clients’ ESG Considerations An Integrated Approach to ESG Application of Proprietary Exclusion List Category Exclusion Policies Firmwide Responsible Human rights violations Exclusion3 Integrated Collaborative Material Controversial weapons1 We ascribe responsibilit
Slide 17: T. Rowe Price Structured Research Equity Strategies
T. Rowe Price Structured Research Equity Strategies As of 31 March 2025 US Structured Global Structured Strategy Research Equity Strategy Research Equity Strategy Benchmark S&P 5002 MSCI All Country World Index2 Expected Tracking Error <1.75% <1.75% Participating Analysts c.30 c.80 Typical Number of
Slide 18: 10 Largest Overweights and Underweights
10 Largest Overweights and Underweights As of 31 March 2025 US Structured Research Equity Representative Portfolio vs. S&P 500 IndexɎ 10 Largest % of % of 10 Largest % of % of Overweights Portfolio Index Difference Underweights Portfolio Index Difference Eli Lilly and Co 1.8% 1.4% 0.4% Berkshire Hat
Slide 19: Participating Investment Analysts
⚫ Baltimore Associate ◼ San Francisco Associate Participating Investment Analysts ▲ New York Associate ◆ Washington DC Associate As of 31 March 2025 ⚫ Ken Allen ◼ Nina Gupta, CFA ⚫ Shinwoo Kim ⚫ Ross MacMillan ⚫ Lee Sandquist ⚫ Ari Weisband, CFA Information Technology Financials Materials Informatio
Slide 20: Please share your feedback
Please share your feedback For every survey completed, £10 will go to Ocean Generation Charity Go to trp.pigeonhole.at Enter passcode USEQUITY2025 Scan QR code Complete surveys T. R O W E P R I C E 20
Slide 21: UK Investment Conference London Tuesday 23rd September
Interested in joining our Investment Conference this year? Please scan the QR codes below to register your interest. UK Investment Conference European Investment Conference London Frankfurt Tuesday 23rd September Thursday 25th September
Slide 22: GIPS Composite Report
GIPS® Composite Report Period Ended 31 December 2024 Figures Shown in U.S. Dollar US Structured Research Equity Composite 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 Gross Annual Returns (%) 3.58 10.90 24.38 -3.94 33.14 20.68 28.51 -18.40 30.33 26.97 Net Annual Returns (%)1 2.19 9.43 22.74 -5.
Slide 23: Fee Schedule
FEE SCHEDULE US Structured Research Equity Composite As of 31 March 2025 The US Structured Research Equity Composite seeks sector- and industry-neutral exposure to the S&P 500 Index, with value added throughstock selection skill. The strategy combines fundamental research with a disciplined portfoli
Slide 24: Additional Disclosures
Additional Disclosures The representative portfolio is an account in the composite we believe most closely reflects current portfolio management style for the strategy. Performance is not a consideration in the selection of the representative portfolio. The characteristics of the representative port
Slide 25: Important Information
Important Information This material is being furnished for general informational and/or marketing purposes only. The material does not constitute or undertake to give advice of any nature, including fiduciary investment advice, nor is it intended to serve as the primary basis for an investment decis
Slide 26: Thank You
D4 T.RowePrice Thank You